Avinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a research report released on Thursday morning. The brokerage issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $5.00 price objective on shares of Avinger in a research note on Thursday, March 21st.

Avinger Stock Performance

Shares of AVGR opened at $1.86 on Thursday. The stock has a 50-day moving average of $2.79 and a two-hundred day moving average of $3.00. Avinger has a one year low of $1.59 and a one year high of $18.00. The stock has a market cap of $3.17 million, a P/E ratio of -0.10 and a beta of 1.12.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($2.49) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($1.14). The business had revenue of $1.86 million during the quarter, compared to the consensus estimate of $2.36 million. Analysts predict that Avinger will post -2.08 EPS for the current fiscal year.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.